Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCA | P06881 | 7/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.32 |
| ▸ | CALCRL | Q16602 | 2/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | FNTA | P49354 | 4/20 | 0.31 |
| ▸ | FNTB | P49356 | 4/20 | 0.31 |
| ▸ | HRAS | P01112 | 1/20 | 0.31 |
| ▸ | KRAS | P01116 | 1/20 | 0.31 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.31 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5657191 | 0.91 | CALCA (0.40) | CALCA | |
| SCHEMBL5661443 | 0.91 | CALCA (0.40) | CALCA | |
| SCHEMBL5660254 | 0.88 | CYP3A4 (0.36) | CALCAROCK2CYP3A4CALCRLBTK | |
| SCHEMBL5659680 | 0.87 | CYP3A4 (0.37) | CALCAROCK2CYP3A4CALCRLBTK | |
| SCHEMBL5657726 | 0.85 | RXRA (0.40) | CALCAROCK2CYP3A4BTKPAK1 | |
| SCHEMBL5660671 | 0.82 | ROCK2 (0.44) | ROCK2CYP3A4 | |
| SCHEMBL5658727 | 0.80 | BTK (0.36) | ROCK2CYP3A4BTK | |
| SCHEMBL5659437 | 0.80 | BTK (0.36) | ROCK2CYP3A4CALCRLBTK | |
| SCHEMBL4862072 | 0.80 | ACACB (0.38) | CALCA | |
| SCHEMBL5661661 | 0.79 | CALCA (0.47) | CALCACALCRL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050227968-A1 | Selected CGRP-antagonists process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-13 | — | — | US | claimed |
| US-7205294-B2 | Selected CGRP-antagonists process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-04-17 | — | — | US | disclosed |
| US-20050227968-A1 | Selected CGRP-antagonists process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227968-A1 | Selected CGRP-antagonists process for preparing them and their use as pharmaceutical compositions | BDKRB1, BDKRB2, CALCRL | CALCA 7/4885ROCK2 4518/4885CYP3A4 1053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.